



Suite 518, Level 5
165-167 Phillip Street
Sydney NSW Australia 2000
PO Box H100
Australia Square NSW Australia 1215
T +61 2 8098 0819
F +61 2 8080 8315
www.mmjphytotech.com.au
info@mmjphytotech.com.au
ABN 91 601 236 417

ASX RELEASE

28 August 2018

Harvest One Investor Presentation

MMJ PhytoTech Limited (ASX: MMJ) ("MMJ") is pleased to attach a copy of an investor presentation recently issued by Harvest One Cannabis Inc. (TSX-V:HVT) ("Harvest One").

Investor and Media Enquiries

Jason Conroy
Chief Executive Officer
T +61 2 8098 0819
jconroy@mmjphytotech.com.au

About MMJ

MMJ is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: <https://www.mmjphytotech.com.au/investors/>



A GLOBAL CANNABIS COMPANY

DISCLAIMER

The information found herein, and any other materials provided by Harvest One Cannabis Inc. (the "Company"), are intended solely for discussion purposes and are not intended as, and do not constitute, an offer to sell or a solicitation of an offer to buy any security, and should not be relied upon by you in evaluating the merits of investing in any securities. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use is contrary to local law or regulation. This information is confidential and should not be distributed, in whole or in part, beyond the recipient and its advisors.

The Company believes the information contained in this document to be reliable but makes no warranty or representation, whether express or implied, and assumes no legal liability for the accuracy, completeness or usefulness of any information disclosed. Any estimates, investment strategies, and views expressed in this document are based upon current market conditions and/or data and information provided by unaffiliated third parties and is subject to change without notice.

This document may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements about strategic plans, including the Company's ability to implement its business development strategy.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance.

All forward-looking information contained herein are given as of the date hereof and are based upon the opinions and estimates of management and information available to management as at the date hereof. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties, including but not limited to market data. The Company believes such information to be accurate but has not independently verified such information. To the extent such information was obtained from third party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not accurate.

*All currency amounts are in Canadian dollars unless stated otherwise.

AT A GLANCE



HARVEST ONE



Licensed Producer




Medical and Pharmaceutical



Consumer Products

HARVEST ONE

OUR GLOBAL FOOTPRINT



Markets

Taking advantages of global changes in legislation.

Strategically located in select global markets.

HVT achieves unique jurisdictional synergies.

Continuously evaluating opportunities across the entire cannabis value chain.

HARVEST ONE



 **united
greeneries**

DUNCAN FACILITY



Current Profile

-  ACMPR Licenses: Cultivation 2016, Sale 2017
-  State of the art 16,000 sq ft production facility
-  1,000 kg annual production capacity
-  Full in-house biochemical QA/QC laboratory
-  31 distinct commercial varieties
-  Level 9 security vault
-  ~\$10+ million in capital investments to date

Expansion Plans

-  16,000 sq ft expansion
-  10,000 sq ft growing area
-  Advanced extraction capabilities
-  Cutting edge R&D laboratory
-  Streamlined in-house packaging and processing

FACILITY EXPANSIONS



LUCKY LAKE - SASKATCHEWAN

- 100% owned by Harvest One
- 60,000 ft² on 18 acres site
- 12,000 kg/y potential production capacity
- Previous capital investment ~\$12m, H1 acquired for \$750k
- 20 ft. bay ceilings allowing multiple levels
- Adjacent to CN rail line and airport
- Ample power and water supply
- Exceptional future development

ALDERGROVE - BC

- Approximately 59,000 ft² facility
- Additional 20 acres available on site for expansion
- Suitable for multiple levels of cultivation
- Minimum 8,000+ kg/y production capacity
- Ample power on site
- Excellent infrastructure in place - adjacent to all major transportation links

OUR CURRENT FACILITIES



DUNCAN

ALDERGROVE

OUTDOOR SITE

LUCKY LAKE



HARVEST ONE

OUTDOOR GROWING



FUTURE LOW COST GROWTH

- 398 acres of prime agricultural land in a unique geographical location
- Advancing site preparation for 2019 growing season
- International outdoor growing consultants already engaged

CANADIAN FRAMEWORK

As the Canadian government finalizes the framework for recreational cannabis cultivation, it is expected that outdoor cultivation will be recognized as an essential component to Canada's cannabis market.

Harvest One's subsidiary, United Greeneries, is well positioned to execute a low-cost growth strategy in Canada once the regulatory framework is finalized.



CONSUMER BRANDS



ROYAL HIGH DRIED FLOWER

VARIETY	SATIVA/INDICA	GENETICS	THC*	CBD*	STRENGTH	DOMINANT TERPENES	REPORTED USES*	REPORTED EFFECTS*
8 BALL KUSH	0/100	Bubba Kush x King Kush	21.8%	< 0.07%	THC: High		Pain, Inflammation, Muscle Spasms	Uplifted, Creative, Focused
SERIOUS KUSH	5/95	OG Kush x White Russian	18.3%	<0.07%	THC: High		Stress, Depression	Relaxed, Happy
SUPER SKUNK	20/80	Skunk #1 x Afghani	16.1%	0.00%	THC: Medium		Pain, Stress	Relaxed, Happy
CHOCOLOPE	95/5	OG Chocolate Thai x Cannalope Haze	15.4%	0.00%	THC: Medium		Stress, Depression	Happy, Energetic, Uplifted, Euphoric
GREAT WHITE SHARK	20/80	Super Skunk x Brazilian x South Indian	15.9%	<0.07%	THC: Medium		Pain, Stress	Uplifted, Happy, Euphoric
NORTHERN LIGHTS MOC	0/100	Northern Lights	12.4%	0.0%	THC: Low		Stress, Pain, Insomnia	Relaxed, Happy
CBD TONIC (AVAILABLE SUMMER 2018)	50/50	Critical Mass x Diesel Tonic	5-7%	8-12%	CBD: High	Results Pending	Inflammation, Pain, Stress	Relaxed, Sleepy, Focused



TERPENE PROFILES

- Myrcene - found in bay leaf, ylang-ylang and wild thyme
- Caryophyllene - found in hops, cloves, basil and oregano
- Limonene - found in limes and lemons
- Pinene - found in pine resin, conifers and sagebrush



United Greeneries Ltd. is a licensed producer of medical marijuana under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR).

*All reported effects and uses are taken from Leafly.com and should not constitute direct medical advice.

*THC and CBD percentages may vary in future lots and batches.

Product availability is subject to change.



HARVEST ONE



OVERVIEW



OVERVIEW

In addition to the Harvest One's ownership of United Greeneries, the company owns Satipharm, which specializes in the development and manufacturing of cannabis-based health products and is the company's medical and health brand.

Since 2015, the company has been producing its own proprietary Gelpell® Microgel Capsules.

The flagship Gelpell® Microgel Capsule delivery technology overcomes bioavailability and consistency issues associated with oral delivery of cannabis-based products.

The Gelpell® Microgel Capsule is the only known product on the market with a pharmaceutical grade GMP (Good Manufacturing Product) production.

GELPELL® TECHNOLOGY

- The Gelpell® Microgel process produces gelatin beads which are approximately 2 mm in length and contain a payload of concentrated cannabinoids.
- The cannabinoids are bound and protected by a three-dimensional natural gelatin matrix.
- When ingested, the gelatin beads create a micro-emulsion which substantially enhances the oral bioavailability of the cannabinoids, and helps ensure accurate and consistent doses.
- These beads are encapsulated and packaged under GMP protocols into 10 mg, 50 mg and 100 mg presentations.


JURISDICTIONS



Satipharm is focused on near-term growth and distribution throughout the EU and in Australia. The company is concurrently preparing to import its products into Canada.

EUROPE

- Near-term growth - significant distribution network across Europe establishing contracts with leading pharma chains.
- Pharmaceutical Central Numbers (PZN codes) were obtained for 10MG and 50MG capsules in early 2017.



AUSTRALIA

- One of the first ever medical cannabis products available to prescribed users in Australia.



CANADA

- Import application submitted to Health Canada to import capsules to Canada to be sold under United Greeneries ACMPR License - anticipated to be a strong near term revenue generator.



CLINICAL TRIALS



PHASE 1

- Trial undertaken by **Phytotech Therapeutics**
- Multi-arm, randomized, crossover study
- 14/15 completers
- Undertaken at Sourasky Medical clinic site
- Pre-cursor to Phase 2 clinical trial for the treatment of pain and spasticity for MS

RESULTS


- ✓ Demonstrable safety and tolerability profile with no significant side effects
- ✓ Higher bioavailability (1.2-1.3x) of active compounds in comparison to GW Pharmaceuticals oromucosal spray – Sativex
- ✓ 8 hours exposure time in the blood

PHASE 2

Currently, two separate Phase 2 trials are in development. One on paediatric refractory epilepsy is underway and another on pain & spasticity due to MS is in development.

Paediatric Refractory Epilepsy Phase 2

The trial is an open-label, single-center clinical study, designed to evaluate the safety, tolerability and efficacy of the Satipharm CBD capsules as an adjunctive treatment to 15 children with treatment-resistant epilepsy, aged 2-15 years.



The trial is undertaken by Israeli-based PhytoTech Therapeutics Ltd

CLINICAL TRIALS - PHASE 2



Study	PTL201: (Pending) Pain & Spasticity	PTL101: Paediatric Refractory Epilepsy
Study Description	A double-blind, randomized, placebo-controlled, parallel-group study of oral PTL201 THC/CBD capsules in subjects with symptoms of pain & spasticity due to MS	Open-label, single-center clinical study of oral administration of PTL101 as an adjunctive treatment to refractory epileptic children
Drug Description	Gelpell® capsules containing THC and CBD	Gelpell® capsules containing highly purified, concentrated CBD
Objective	Safety, tolerability and efficacy	Safety, tolerability and efficacy
Subjects	~70 MS patients	~15 pediatric patients with refractory epilepsy

HARVEST ONE

**DREAM
WATER[®]**



OVERVIEW

DREAM WATER®



HARVEST ONE

OVERVIEW

The recent acquisition of Dream Water Products Global places Harvest One at the forefront of the all important sleep and relaxation categories.

The brand is growing rapidly in Canada and the United States with over 30,000 current retail doors.

Dream Water is in the process of launching an international licensing and distribution division that Harvest One expects to expand rapidly over the next 2 years.

The brand's current SKU line-up allows for immediate international expansion with non-cannabis related products to gain brand and distribution footholds in other countries where legislation will take time to allow for Cannabis based products to be sold legally.

SKU DEVELOPMENT



The natural sleep and relaxation categories are among the fastest growing OTC and Rx categories globally.



Harvest One and Dream Water recognized the opportunity to build multiple line extensions with Dream Water branded CBD and THC infused products.



Presently we know of no other Cannabis company with a sleep strategy that already has Dream Water's widespread brand recognition and consumer acceptance with 30,000+ retail outlets moving daily volume.



Dream Water was voted Canada's Product of the Year for the Wellness Innovation category in 2017 and was awarded 'Best in Show' among 20 other category winners by Chatelaine magazine.



DREAM WATER®



KENDALL JENNER

RUMER WILLIS



PARIS HILTON



DARRYL SITTLER

IN THE MEDIA

CELEBRITY MENTIONS

FINANCIAL INFORMATION

CAPITAL STRUCTURES

Market Capitalization	\$140 million
Issued Shares	176,621,452
Warrants	33,356,632 (\$1.00 -\$2.30)
Options	6,900,000 @ \$0.75 400,000 @ \$1.81 8,000,000 @ \$0.77
Cash	\$58 million
Debt	No Debt
52 week Low/High	\$0.47 - \$2.20
Insider Holdings	Approx. 30% (MMJ Holding)

RECENT HIGHLIGHTS

- On December 14, 2017, Harvest One closed a bought deal debenture offering of \$20,125,000
- On January 31st, 2018, Harvest One announced it successfully closed \$40,250,000 public financing of Units, including exercise of over-allotment option in full.
- On April 5th, 2018 Harvest One Converts all Outstanding Debentures to Ordinary Shares and Maintains \$80m Cash Position
- On May 3rd, 2018 Harvest One completes the acquisition of Dream Water Global for approximately \$34.5m in cash and shares

MANAGEMENT TEAM


Grant Froese	Andrew Kain	Nick Maltchev	Lisa Dea	Daniela Vaschi
CEO	COO	CTO	CFO	COS
<p>Mr. Froese is a retail industry veteran with 38 years of experience at Loblaw, Canada’s largest food retailer, with his most recent position being Chief Operating Officer prior to his short-lived retirement in April 2017.</p> <p>Since August 2017, Froese served as the Chief Executive Officer for Marquee Health Group, a late stage applicant under the Access to Cannabis for Medical Purposes Regulation (ACMPR) where he gained valuable industry experience and insight.</p> <p>Mr. Froese has extensive experience in supply chain management, digital/ecommerce businesses, marketing, brand management and operations management.</p>	<p>Andrew Kain is a lawyer by profession with almost 25 years of extensive corporate, financial and legal experience. For 15 years, he was General Counsel to a US\$5+ billion global hedge fund that operated a proprietary quantitative trading platform and managed a US\$2+ billion fund of funds portfolio, where he worked with investment banks, brokerage houses, exchanges and regulatory bodies in capital markets around the globe.</p> <p>Most recently Andrew was in private practice providing general corporate, financial and advisory services to start-up and early stage companies in emerging industries.</p> <p>Andrew is also a founder and President of Windular Research and Technologies Inc., a privately held corporation that provides innovative renewable energy systems, consulting and advisory services to the global telecommunications industry.</p>	<p>Mr. Maltchev has 25 years of technology experience and 13 years cannabis industry experience with Advanced Nutrients. Held several positions including Information Technology Manager, COO and General Manager.</p> <p>Nick holds a BBA degree, as well as other designations in project management, cybersecurity and computer science.</p> <p>Nick is currently in the process of finishing an MBA in management information systems.</p>	<p>Ms. Dea has over 20 years of experience in the finance, securities and accounting fields. Ms. Dea has been the CFO of several TSX and TSX-V listed companies where she was responsible for corporate strategy, all aspects of finance and legal, debt and capital market activities, internal and external public reporting, financial controls, processes and corporate governance.</p> <p>She has been instrumental in helping several companies grow from the development stage to large-scale commercial operations. Prior to her time in industry, Lisa spent eleven years at Deloitte & Touche LLP, achieving the position of Senior Manager. Ms. Dea obtained her Chartered Accountants designation in 1997 and also holds a B.Comm from the University of British Columbia.</p>	<p>Ms. Vaschi is an Organizational Psychologist from the European Union with more than ten years of multidisciplinary experience, including over 6 years at the corporate level within global operations.</p> <p>She has a successful background in developing business structures from ground zero, as well as rebuilding infrastructure after mergers and acquisitions, downsizing and turnarounds.</p> <p>She is an active member of the International Organization Development Association, performing an ongoing meta-analytic research on Emotional Intelligence.</p>

BOARD OF DIRECTORS

Grant Froese	Peter Wall	Jason Bednar
<p>CEO</p>	<p>Chairman</p>	<p>Director</p>
<p>Mr. Froese is a retail industry veteran with 38 years of experience at Loblaw, Canada’s largest food retailer, with his most recent position being Chief Operating Officer prior to his short-lived retirement in April 2017.</p> <p>Since August 2017, Froese served as the Chief Executive Officer for Marquee Health Group, a late stage applicant under the Access to Cannabis for Medical Purposes Regulation (ACMPR) where he gained valuable industry experience and insight.</p> <p>Mr. Froese has extensive experience in supply chain management, digital/ecommerce businesses, marketing, brand management and operations management.</p>	<p>Mr. Wall is a corporate lawyer based in Perth, Western Australia and is a Partner at one of Australia's leading corporate and commercial law firms.</p> <p>He graduated from the University of Western Australia in 1998 with a Bachelor of Laws and Bachelor of Commerce (Finance) and subsequently completed a Masters of Applied Finance and Investment with FINSIA (formerly the Securities Institute of Australia).</p> <p>Mr. Wall has a wide range of experience in all forms corporate and commercial law, with a particular focus on mergers and acquisitions, IPOs, back door listings and equity capital markets transactions.</p>	<p>Mr. Bednar is a Chartered Accountant with more than 18 years of direct professional experience in the financial and regulatory management of companies listed on the TSX, TSX-V, American Stock Exchange and ASX.</p> <p>He is currently the CFO and director of Canacol Energy Ltd., an oil and gas E&P company with an enterprise value of ~US\$650M. Mr. Bednar has significant public company management experience having held CFO positions at several international oil and gas companies, most notably as founding CFO of Pan Orient Energy Corp.</p> <p>He previously sat on the board of directors of several internationally-focused E&P companies, including being the past Chairman of Gallic Energy Ltd. Mr. Bednar holds a Bachelor of Commerce degree from the University of Saskatchewan.</p>

ANALYST COVERAGE

FIRM	ANALYST	PHONE	EMAIL
Haywood Securities	Neal Gilmer	+1 (416) 507-2300	ngilmer@haywood.com
Mackie Research	Greg McLeish	+1 (416) 860-7600	gmcleish@mackieresearch.com



THANK YOU

INVESTOR RELATIONS

For more information about Harvest One, please contact:

Colin Clancy

Investor Relations

+ 1 (877) 915-7934

cclancy@mmj.ca



HARVEST ONE